GlassScriptPhysician profile
Sudha Nayar
NPI 1396739389
$9,870.23
in general payments reported to CMS, 2019-2025
31 companies · $2,026 in 2025
The $2,026 reported for 2025 was more than what 89% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,029 · 2020: $914 · 2021: $1,280 · 2022: $1,261 · 2023: $1,803 · 2024: $1,558 · 2025: $2,026.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,297 · Education: $89.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,297.29 |
| Education | $89.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,124.82 | 2019-2025 | Farxiga, Lokelma, Flumist Quadrivalent |
| Vifor Pharma, INC. | $1,061.81 | 2019-2025 | Veltassa |
| Bayer Healthcare Pharmaceuticals INC. | $899.15 | 2021-2025 | |
| Travere Therapeutics, INC. | $859.86 | 2019-2025 | Filspari |
| Opko Pharmaceuticals, LLC | $766.05 | 2019-2025 | Rayaldee |
| Otsuka America Pharmaceutical, INC. | $645.61 | 2019-2025 | Jynarque, Voyxact |
| Amgen INC. | $588.43 | 2019-2025 | Tavneos, Parsabiv |
| Fresenius USA Marketing, INC. | $537.59 | 2019-2025 | Velphoro, Korsuva, Velphoro |
| Akebia Therapeutics INC | $447.86 | 2019-2025 | Auryxia, Vafseo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $404.80 | 2023-2025 | Jardiance |
| Calliditas Therapeutics US INC. | $341.33 | 2023-2025 | Tarpeyo |
| Daiichi Sankyo INC. | $311.84 | 2021-2023 | Injectafer |
| Mallinckrodt Hospital Products INC. | $306.65 | 2022-2025 | Acthar, Terlivaz |
| Alexion Pharmaceuticals, INC. | $303.61 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $262.99 | 2023-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $180.88 | 2024-2025 | Ibsrela |
| Glaxosmithkline, LLC. | $175.41 | 2019-2023 | Benlysta |
| Aurinia Pharma U.S., INC. | $125.98 | 2021-2022 | |
| Nxstage Medical, INC. | $101.36 | 2021-2023 | Nxstage System One, Liberty Select Cycler |
| Apellis Pharmaceuticals, INC. | $72.49 | 2025 | Empaveli |
| Horizon Therapeutics Plc | $70.04 | 2023 | Krystexxa |
| Ani Pharmaceuticals, INC. | $61.57 | 2025 | Purified Cortrophin Gel |
| Novo Nordisk INC | $39.63 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Ultragenyx Pharmaceutical INC. | $37.97 | 2019-2022 | |
| Bard Peripheral Vascular, INC. | $29.18 | 2023 | |
| Cycle Pharmaceuticals INC | $24.48 | 2025 | Venxxiva |
| Kyowa Kirin, INC. | $20.98 | 2024 | Crysvita |
| Tactile Systems Technology INC | $20.74 | 2025 | Flexitouch Plus, Nimbl |
| Genzyme Corporation | $16.86 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.56 | 2019 | |
| Amag Pharmaceuticals, INC. | $13.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sudha Nayar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.